Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?
نویسندگان
چکیده
منابع مشابه
Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
BACKGROUND In patients with non-metastatic gastric cancer surgery still remains the treatment of choice. Postoperative radiochemotherapy with 5-fluorouracil and leucovorin significantly improves the treatment outcome. The oral fluoropyrimidines, such as capecitabine, mimic continuous 5-fluorouracil infusion, are at least as effective as 5-fluorouracil, and such treatment is more comfortable for...
متن کاملAdjuvant radiochemotherapy for rectal cancer.
One of the basic questions for radiation oncologists is what we hope to achieve from treatments that are adjuvant to surgery. Can we achieve a better local control? Is there a decrease in metastatic disease? Can we see an effect on overall survival? Although some questions remain to be answered, some general recommendations for the treatment of rectal cancer can be given. Since the NIH recommen...
متن کاملPrognostic factors for gastrectomy in elderly patients with gastric cancer
BACKGROUND The aim of the present study was to investigate the age-specific prognostic factors in patients who underwent gastrectomy for gastric cancer. METHODS The medical records of 366 patients with gastric cancer who underwent surgical resection at our hospital between January 2007 and December 2014 were retrospectively reviewed. Of the 366 patients, 117 were aged 75 years or older and 24...
متن کاملPrognostic factors in patients with loco-regionally advanced gastric cancer
BACKGROUND The aim of this study was to investigate epidemiologic and prognostic factors relevant to the treatment of loco-regionally advanced gastric cancer (GC). METHODS Two hundred and fifty-five patients with GC were identified in Uppsala County between 2000 and 2009. Patient records were analyzed for loco-regionally advanced GC defined as tumor with peritoneal involvement, excluding sero...
متن کامل“How should we treat older patients with Metastatic Colorectal Cancer, A Review”
Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Gastroenterology
سال: 2016
ISSN: 1007-9327
DOI: 10.3748/wjg.v22.i3.1131